Active Investments

Constellation Pharma

Private

Acceleron Pharma

Public (NASDAQ: XLRN)

Celladon Corporation

Public (NASDAQ: CLDN)

Cymabay Therapeutics

Public (OTCQB: CYMA)

AVEO Pharma

Public (NASDAQ: AVEO)

Infinity Pharma

Public (NASDAQ: INFI)

Alumni Investments

Coley Pharma

Acquired by Pfizer

Renovis

Acquired by Evotec

Memory Pharma

Acquired by Roche

Icagen

Acquired by Pfizer

Caliper

Public (NASDAQ: CALP)

Sonic Innovations

Acquired by William Demant Holding

Triangle Pharma

Acquired by Gilead

SUGEN

Acquired by Pharmacia & Upjohn

Athena Neurosciences

Acquired by Elan

IDEC Pharma

Acquired by Biogen

Sepracor

Public (NASDAQ: SEPR)

IDEXX Labs

Public (NASDAQ: IDXX)

Centocor

Acquired by Johnson & Johnson

Genetics Institute

Acquired by Wyeth

Tony Evnin Partner

Focus Areas: Biotechnology, Medical Devices
Location: New York

Tony joined Venrock in 1974 and built the firm’s healthcare franchise, helping to shape the modern biotechnology industry. He currently serves on the Board of Directors of two public companies, AVEO Pharmaceuticals (NASDAQ: AVEO) and Infinity Pharmaceuticals (NASDAQ: INFI), as well as on the Board of Directors of Constellation Pharmaceuticals, a private company. Past investments include Acceleron (NASDAQ: XLRN), Celladon (NASDAQ: CLDN), Centocor (IPO/ acquired by Johnson & Johnson), Coley Pharmaceutical Group (IPO/ acquired by Pfizer), Genetics Institute (IPO/ acquired by Wyeth), Icagen (IPO/ acquired by Pfizer), IDEC Pharmaceuticals (IPO/ merged with Biogen), IDEXX Laboratories (NASDAQ: IDXX), Millennium Pharmaceuticals (IPO/acquired by Takeda) and Sepracor (IPO/acquired by Dainippon Sumitomo). More than 30 of his investments have been through an IPO during his Venrock tenure.

Tony started his career as a Research Scientist and Group Leader in Organic Chemistry at Union Carbide and as Director of Product Development at Story Chemical. He serves as a Trustee of The Rockefeller University, as a Trustee of The Jackson Laboratory, as a Member of the Boards of Overseers and Managers of Memorial Sloan-Kettering Cancer Center, as a Director of the New York Genome Center, as a Member of the Board of Directors of the Albert and Mary Lasker Foundation, and as a Trustee Emeritus of Princeton University. Tony is focused on building valuable companies that address important medical needs of the world, while providing strong returns for investors.

Tony received his A.B. in Chemistry from Princeton University and his Ph.D. in Chemistry from the Massachusetts Institute of Technology.

Active Companies

Constellation Pharma

Acceleron Pharma

Celladon Corporation

Cymabay Therapeutics

AVEO Pharma

Infinity Pharma

Alumni Companies

Coley Pharma

Renovis

Memory Pharma

Icagen

Caliper

Sonic Innovations

Triangle Pharma

SUGEN

Athena Neurosciences

IDEC Pharma

Sepracor

IDEXX Labs

Centocor

Genetics Institute

Genetics Institute developed pharmaceuticals based on leading edge functional genomics technologies and proprietary disease models to treat a wide variety of human disease conditions